Pharmaxis Ltd (AU:SNT) has released an update.
Pharmaxis Ltd has nearly reached its recruitment goal for a Phase 2 myelofibrosis study, with promising interim safety results and plans to present data in December. Progress has been made in developing protocols for upcoming myelodysplastic syndrome studies, with significant non-dilutive funding secured. Despite exiting its mannitol business and facing a legal dispute with Arna Pharma, the company has raised $4m to ensure continued clinical trials.
For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.
